Laboratory of Experimental
Therapeutics for Movement
Disorders, which conducts
clinical trials of new therapies
for Parkinson's disease,
Huntington's disease
and other movement
disorders. Dr. Feigin is
particularly interested
in utilizing PET imaging
methods as a biomarker for
neurodegenerative disorders
in the preclinical phase
of illness.
focuses on how biophysics
and bioengineering can be
applied to neuroscience,
and particularly to the study
of disease mechanisms in
movement disorders and
other neurodegenerative
conditions.
is on clinical research and
patient care. He is interested
in lupus and rheumatoid
arthritis, and is involved
with clinical trials looking at
new therapeutic targets for
these diseases. He is also
investigating the link between
metabolism and disease
activity in patients with lupus.
induction and pathogenicity
of DNA-reactive antibodies
in lupus. These studies
are designed to provide
new strategies to prevent
autoimmunity or protect
against tissue damage in
lupus. She also studies the
contribution of maternal
antibody to abnormal
brain development.
sepsis. Laboratory work
includes determinants of
organ dysfunction, with
emphasis on mitochondrial
dysfunction, aberrant
signal transduction and
abnormalities of neural
and endocrine control
mechanisms. Clinical projects
focus on epidemiologically
based definitions of sepsis.
He is also involved in both
laboratory and clinical
investigations throughout the
Department of Pediatrics.
imaging research program in
brain disease. His program
has developed novel imaging
techniques to characterize
and quantify neural circuits
in neurodegenerative
disorders and to study
their modulation by using
functional imaging with PET
and fMRI. This approach has
provided unique insights
into Parkinson's disease and
related movement disorders.
of substance abuse on brain
function and structure.
He has researched brain
exposure to caffeine, tobacco,
alcohol, marijuana, cocaine,
methamphetamine, opiates,
heroin and chemical solvents,
and most recently focused on
developing a novel treatment
for drug abuse.
interests bring together
behavioral medicine and
creative/medical art therapy
with neuroscience. Her recent
research projects connect art
therapy with those diagnosed
with Parkinson's disease,
cancer and connecting
the creative process to
neurological responses.